Search

EHA European Hematology Exam 2018 Report

1. Method
a. Format
The second European Hematology Exam took place on Wednesday, June 13 in Stockholm, Sweden, and Bern, Switzerland. The Exam consisted of 100 multiple choice questions, covering all eight sections of the European Hematology Curriculum.

Read more

Multiple Myeloma

The SWG Multiple Myeloma has traditionally been composed of members of the European Myeloma Network (EMN). EMN is a dedicated academic, non-profit organization for clinical research in multiple myeloma.

Read more

Statement

The European Hematology Association (EHA), a dedicated community of healthcare professionals, who work tirelessly "Towards prevention, cure, and quality of life for all patients with blood disorders", expresses its deep concern and sorrow over the ongoing violence and humanitarian crisis…

Read more

ESH-EBMT-EHA-IPIG 3rd Translational Research Conference

ESH-EBMT-EHA-IPIG 3rd Translational Research Conference on Bone Marrow Failure and Leukaemia Predisposition Syndromes

Date: November 15-17, 2024
Location: Paris, France

Chairpersons: Carmem Bonfim, Tim Brümmendorf, Antonio Risitano, Sharon Savage
Scientific Committee: Beatrice Drexler, Carlo Dufour, Morag Griffin, Régis Peffault de Latour

With the support of the Severe Aplastic…

Read more

Publications

HemaSphere - the official open access journal of EHAHemaSphere is the official open access, peer-reviewed journal of EHA, supporting hematology researchers by offering a fast and constructive review process and low publication fees.

Read more

EHA, in partnership with ISTH, award two fellows to support global educational opportunities

EHA and the International Society on Thrombosis and Hemostasis (ISTH) jointly awarded two joint ISTH-EHA Training Fellowships to Araci Rondon (The Netherlands) and Dianne van der Wal (Australia).

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more